Cold sore virus modified to fight kidney cancer in new trial
NCT ID NCT07218692
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests a combination of RP2 (a modified herpes simplex virus that targets and destroys tumor cells) and tivozanib (a drug that blocks tumor blood vessel growth) in 35 patients with metastatic kidney cancer that worsened after immunotherapy. The goal is to see if the combination is safe and can shrink tumors. Participants will receive the virus injection and oral tivozanib, along with biopsies and imaging.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- RP2 (a modified herpes simplex virus) and tivozanib hydrochloride
- What this could lead to
- If successful, this combination could offer a new treatment option for patients with advanced kidney cancer that has stopped responding to immunotherapy.
- What could go wrong
- This is a small, early-phase trial (35 participants) testing safety and effectiveness. The virus-based therapy may cause side effects, and results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED CLEAR CELL RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States
-
City of Hope at Irvine Lennar
Irvine, California, 92618, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill rewrite the genetic story of resistant kidney cancer?
- Can a pill boost the immune system to fight Hard-to-Treat cancers?
- Can a rapid drug switch outsmart advanced kidney cancer?
- Can a tracer that hunts unstable iron light up hidden tumors?
- Old drug, new hope: mercaptopurine tested against rare cancer syndrome
- New imaging agent aims to spot Hard-to-Find kidney cancer spread